PR

PROCEPT BioRobotics Corporation Common Stock Earnings Recaps

PRCT Health Care 3 recaps
Next earnings: November 3, 2026 (estimated) · full calendar
Q2 2026 Aug 7, 2026

Shares rose 5.2% post-earnings, reflecting market approval of stronger-than-expected system demand, notably robust HYDROS placements, and disciplined pricing that drove higher average selling prices.

Key takeaways
  • Total revenue reached $94.5 million, up 19% year-over-year.
  • Procedure volume grew 21% to over 13,100 U.S. procedures; however, growth was softer than anticipated, driven by weaker legacy AQUABEAM account performance.
  • HYDROS system placements were strong with 65 units placed, including 50 new installs and 14 replacements, underscoring successful rollout efforts.
  • HYDROS average selling price increased to approximately $495,000, up from $485,000 in Q1 and $435,000 in full-year 2025.
  • Strategic commercial initiatives such as salesforce realignment, replacement upgrades, and patient activation pilots are underway to support sustainable growth.
Full recap
Q1 2026 Apr 30, 2026

Shares climbed 4.4% following PROCEPT BioRobotics’ Q1 2026 results, as investors responded positively to accelerated margin recovery, record system pricing, and confirmation of the company’s full-year profitability and growth objectives.

Key takeaways
  • Q1 2026 revenue reached $83.1 million, up 20% year-over-year, in line with management’s stated expectations despite modest procedural impact from commercial realignment.
  • Gross margin improved sharply to 65%, up from 61% in Q4 2025, reaching the company’s full-year guidance three quarters early; management now expects further sequential margin gains throughout 2026.
  • U.S. Hydros system average selling price hit an all-time high of ~$485,000 (14% increase vs. Q4 2025), while handpiece ASPs rose 5% quarter-over-quarter and 10% year-over-year.
  • Company reiterates full-year system placement plans, with 49 U.S. Hydros systems sold in Q1 (including 2 replacements) and strong initial response to the AQUABEAM replacement program.
  • International expansion advanced with 7 Hydros systems sold in the UK and continued pipeline growth; regulatory momentum included a major clinical guideline upgrade in Europe and FDA clearance of second-generation software.
Full recap
Q3 2025 Nov 5, 2025

PROCEPT BioRobotics reported robust third quarter 2025 results, achieving $83.3 million in total revenue, a 43% year-over-year increase, driven by strong capital system sales. The company remains focused on enhancing procedure utilization and expanding market awareness for its innovative Aquablation therapy.

Key takeaways
  • Total revenue reached $83.3 million, with U.S. sales contributing $73.9 million, showcasing solid growth amidst market scrutiny.
  • 58 U.S. capital systems shipped in the quarter, indicating a stable pricing environment despite tightening capital budgets in large hospital systems.
  • Organizational changes aimed at improving commercial execution, including expedited new account launches and a sharpened focus on international markets.
  • Potential expansion into prostate cancer treatment, supported by the ongoing WATER IV clinical trial, highlights the long-term growth opportunities beyond BPH.
  • Commitment to enhancing patient awareness and accelerating therapy adoption, leveraging new talent within leadership.
Full recap

Go deeper on PRCT and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.